Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 7;7:4866. doi: 10.1038/s41598-017-04978-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Peripheral lymphocyte compositions are dynamic after HSRT. (a) Peripheral blood samples were obtained from the 6 enrolled NSCLC patients on the day before HSRT (pretreatment, pre; dark circle), immediately after the completion of HSRT (post-treatment, pos; dark square) and at 3 weeks post-treatment (pos-3w; dark triangle). PBMCs were harvested and labeled with fluorochrome-coupled antibodies. The percentage of CD3⁺ T cells in CD45⁺ cells (a), CD4⁺ T cells in CD3⁺ T cells (b), CD8⁺ T cells in CD3⁺ T cells (c), CD20⁺ B cells in CD45⁺ cells (d), CD4⁺Foxp3⁺ cells in CD45⁺ cells (e), CD14⁺ cells in CD45⁺ cells (f), TCRvδ1⁺ cells in CD45⁺ cells (g), TCRvδ2⁺ cells in CD45⁺ cells (h), and DC in CD45⁺ cells (i) were analyzed. All statistical analyses were performed versus Pre(pretreatment) using ANOVA with Bonferroni’s post-test. *p < 0.0167, **p < 0.01; ***p < 0.001.